Related Experiment Video

Updated: Nov 19, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

Ravi Salgia1, Rebecca Pharaon1, Isa Mambetsariev1

  • 1Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.

Cell Reports. Medicine
|February 1, 2021
PubMed

Insights

Targeting KRAS, a common cancer driver, is now possible in non-small cell lung cancer (NSCLC). Researchers are developing new KRAS-targeted drugs and immunotherapies to treat this challenging disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • KRAS is a key oncogene in various solid tumors, notably non-small cell lung cancer (NSCLC).
  • Historically considered undruggable due to its challenging molecular structure.
  • Recent advancements have spurred the development of targeted therapies and immunotherapies.

Purpose of the Study:

  • To review emerging therapeutic strategies for KRAS-mutant NSCLC.
  • To highlight the progress in overcoming KRAS as a therapeutic target.
  • To discuss the potential of novel treatments in clinical trials.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of KRAS-targeted small-molecule inhibitors.
  • Evaluation of immunotherapeutic approaches targeting KRAS neoantigens.

Main Results:

  • Several novel KRAS inhibitors and combination therapies are in clinical development.
  • Immunotherapies are showing promise in generating anti-tumor immune responses.
  • Targeting KRAS mutations offers a new avenue for NSCLC treatment.

Conclusions:

  • KRAS-mutant NSCLC is becoming an actionable target with emerging therapies.
  • A combination of targeted drugs and immunotherapy may offer improved outcomes.
  • Further research and clinical trials are crucial to validate these promising approaches.
Keywords:
KRASclinical trialsimmunotherapynon-small cell lung cancerpersonalized medicinetargeted therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K